175 related articles for article (PubMed ID: 37492166)
1. Regorafenib in Glioblastoma Recurrence: How to Deal With MR Imaging Treatments Changes.
Gaudino S; Marziali G; Giordano C; Gigli R; Varcasia G; Magnani F; Chiesa S; Balducci M; Costantini AM; Della Pepa GM; Olivi A; Russo R; Colosimo C
Front Radiol; 2021; 1():790456. PubMed ID: 37492166
[TBL] [Abstract][Full Text] [Related]
2. Modification of MRI pattern of high-grade glioma pseudoprogression in regorafenib therapy.
Mansour M; Vitale V; Lombardi G; Riva G; Pancheri F; Zanusso M
J Med Imaging Radiat Oncol; 2022 Apr; 66(3):414-418. PubMed ID: 34169667
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. PET/MR in recurrent glioblastoma patients treated with regorafenib: [
Lombardi G; Spimpolo A; Berti S; Campi C; Anglani MG; Simeone R; Evangelista L; Causin F; Zorzi G; Gorgoni G; Caccese M; Padovan M; Zagonel V; Cecchin D
Br J Radiol; 2022 Jan; 95(1129):20211018. PubMed ID: 34762492
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.
Zeiner PS; Kinzig M; Divé I; Maurer GD; Filipski K; Harter PN; Senft C; Bähr O; Hattingen E; Steinbach JP; Sörgel F; Voss M; Steidl E; Ronellenfitsch MW
J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31766326
[TBL] [Abstract][Full Text] [Related]
6. Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review.
Gatto L; Franceschi E; Tosoni A; Di Nunno V; Maggio I; Tonon C; Lodi R; Agati R; Bartolini S; Brandes AA
Clin Case Rep; 2021 Aug; 9(8):e04604. PubMed ID: 34457284
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in Recurrent Glioblastoma Patients: A Large and Monocentric Real-Life Study.
Lombardi G; Caccese M; Padovan M; Cerretti G; Pintacuda G; Manara R; Di Sarra F; Zagonel V
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572958
[TBL] [Abstract][Full Text] [Related]
8. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Dhermain F
Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging-derived parameters to predict response to regorafenib in recurrent glioblastoma.
Martucci M; Ferranti AM; Schimperna F; Infante A; Magnani F; Olivi A; D'Alessandris QG; Gessi M; Chiesa S; Mazzarella C; Russo R; Giordano C; Gaudino S
Neuroradiology; 2023 Oct; 65(10):1439-1445. PubMed ID: 37247021
[TBL] [Abstract][Full Text] [Related]
11. Data-driven grading of brain gliomas: a multiparametric MR imaging study.
Caulo M; Panara V; Tortora D; Mattei PA; Briganti C; Pravatà E; Salice S; Cotroneo AR; Tartaro A
Radiology; 2014 Aug; 272(2):494-503. PubMed ID: 24661247
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility and Tumor Size Changes During the Time Course of Standard Treatment in Recurrent Glioblastoma.
van Leyen K; Roelcke U; Gruber P; Remonda L; Berberat J
J Neuroimaging; 2019 Sep; 29(5):645-649. PubMed ID: 31112344
[TBL] [Abstract][Full Text] [Related]
13. Dramatic response to regorafenib in early glioblastoma progression: case report and review of the literature.
De Felice M; De Marinis P; Martin G; Bruscella S; De Bellis A; Poliero L; Turitto G
Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5008-5013. PubMed ID: 35916797
[TBL] [Abstract][Full Text] [Related]
14. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
15. MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences.
Tien RD; Felsberg GJ; Friedman H; Brown M; MacFall J
AJR Am J Roentgenol; 1994 Mar; 162(3):671-7. PubMed ID: 8109520
[TBL] [Abstract][Full Text] [Related]
16. [Diffusion weighted MR: principles and clinical use in selected brain diseases].
Nistri M; Mascalchi M; Moretti M; Tessa C; Politi LS; Orlandi I; Pellicanò G; Villari N
Radiol Med; 2000 Dec; 100(6):470-9. PubMed ID: 11307509
[TBL] [Abstract][Full Text] [Related]
17. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
[TBL] [Abstract][Full Text] [Related]
18. MR imaging of glioblastoma in children: usefulness of diffusion/perfusion-weighted MRI and MR spectroscopy.
Chang YW; Yoon HK; Shin HJ; Roh HG; Cho JM
Pediatr Radiol; 2003 Dec; 33(12):836-42. PubMed ID: 14564423
[TBL] [Abstract][Full Text] [Related]
19. Identification of Early Response to Anti-Angiogenic Therapy in Recurrent Glioblastoma: Amide Proton Transfer-weighted and Perfusion-weighted MRI compared with Diffusion-weighted MRI.
Park JE; Kim HS; Park SY; Jung SC; Kim JH; Heo HY
Radiology; 2020 May; 295(2):397-406. PubMed ID: 32154775
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
